Clinical Trials Browser

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT07391670 2026-05-15

IMFINZI-subQ

Phase 1 Recruiting

40 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT05374603 2026-05-14

SOUND

Phase 2 Active not recruiting

47 enrolled

Thoracic

Lung Neoplasms

NCT06467357 2026-05-14

DESTINY-BTC01

Phase 3 Recruiting

620 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT06591650 2026-05-14

GCND

Phase 2 Recruiting

33 enrolled

GastrointestinalGenitourinary

Gallbladder Cancer Unresectable

NCT07361497 2026-05-14

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Phase 3 Recruiting

850 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03606967 2026-05-13

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Recruiting

70 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03706690 2026-05-13

PACIFIC-5

Phase 3 Active not recruiting

407 enrolled 22 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Phase 2 Recruiting

115 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04379596 2026-05-13

DG-03

Phase 2 Recruiting

450 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT04550260 2026-05-13

KUNLUN

Phase 3 Active not recruiting

640 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04628767 2026-05-13

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

249 enrolled

Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT05411094 2026-05-13

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Phase 1 Recruiting

18 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06058663 2026-05-13

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Phase 1 Recruiting

16 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT06732401 2026-05-13

CLEAR

Phase 3 Active not recruiting

630 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07012798 2026-05-13

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

Phase 2 Recruiting

30 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT02264678 2026-05-12

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Phase 1 Active not recruiting

354 enrolled

Gynecologic

Ovarian Neoplasms

NCT02453282 2026-05-12

MYSTIC

Phase 3 Active not recruiting

1,118 enrolled 40 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

TOPAZ-1

BOLSTER

PATAPSCO

Ablatio

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

SAMETA

NeoCOAST-2

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

PanTumor-101

DIAMOND

DeLLphi-312

DeLLphi-313

REVIVE

(DeLLphi-310)

ALBORAN

STAGGER

ROSY-D

SUNRAY-02

PACIFIC-8

PACIFIC-9

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

MK-7339-012

RAINBO

LADOGA

IMFINZI-subQ

SOUND

DESTINY-BTC01

GCND

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

PACIFIC-5

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

DG-03

KUNLUN

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

CLEAR

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

MYSTIC